ABSTRACT
INTRODUCTION
Hypertensive disorders such as gestational hypertension (GH), chronic hypertension and pre-eclampsia (PE) complicate up to 10% of pregnancies, with the incidence of PE being between 2% and 8% [1] [2] [3] . Although maternal mortality due to PE is decreasing in the UK, it remains a leading cause of direct maternal death worldwide, as well as a cause of maternal, fetal and neonatal morbidity. The most recent report of Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK made a number of recommendations for the management of women with hypertensive disorders of pregnancy, including the need for an increased schedule of checks and for prompt control of hypertension [4] [5] [6] . Current care of women who develop hypertensive disorders of pregnancy focuses on outpatient attendance to a day assessment unit (DAU) at their maternity hospital for blood-pressure monitoring and urine testing, as well as blood tests and fetal monitoring (cardiotocography (CTG) and/or ultrasound scan), if indicated. The frequency of visits depends on the underlying diagnosis but is usually two to three times a week 7 . Admission to an antenatal ward is commonplace when initiating medication for uncontrolled blood pressure or if there is suspicion of PE. This frequent monitoring can represent a source of anxiety to these women and their families, it is demanding in terms of time, transport costs and work absence, and has significant cost implications for limited healthcare resources.
Home blood-pressure monitoring (HBPM) is used extensively outside pregnancy and is an accurate and patient-acceptable alternative to clinic visits. HBPM is recommended by the British Hypertension Society and National Institute for Health Research who have produced evidence to support its implementation 8, 9 . They advise that more research is needed into HBPM in pregnancy which reflects the need for this innovation to be transferred to the obstetric setting 8, 9 . The American College of Obstetricians and Gynecologists advocates the use of HBPM in patients with chronic hypertension and other professional bodies recognize its potential 8, 10, 11 . HBPM is acceptable to pregnant patients and does not increase anxiety 12, 13 . The main objective of this study was to undertake a health economic analysis of the cost-effectiveness of HBPM compared with traditional monitoring in hypertensive pregnancy.
METHODS

Population and study design
This was a cost-minimization study involving a cohort of hypertensive pregnant women enrolled in a HBPM pathway and a control group managed according to the traditional pathway of regular DAU visits for blood-pressure monitoring. Since the patients presented equivalent health outcomes and the main aim of the study was to assess cost savings of the new pathway compared with the conventional one, we entitled this a cost-minimization study. The study perspective was the direct cost to the healthcare system. Patients presented either via referral to the hypertension clinic or to the DAU at St George's University Hospital NHS Foundation Trust between December 2013 and November 2016. Pregnant women with a history of prepregnancy hypertension or at increased risk of developing hypertension in pregnancy, systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, proteinuria ≤ 1+ on urine dipstick testing, normal full blood count, normal liver and renal function blood tests and who spoke English were included in the study. Exclusion criteria were maternal age < 16 years at booking, systolic blood pressure > 155 mmHg, diastolic blood pressure > 100 mmHg, proteinuria ≥ 2+ on urine dipstick testing, severe PE, intrauterine fetal growth restriction, significant mental health concerns, inability to give valid consent or language barrier. The above blood-pressure parameters were selected in order to avoid inclusion of patients who could potentially develop severe hypertension at home. This is in line with the recommendation of hospital admission for systolic blood pressure of 160 mmHg or diastolic blood pressure of 110 mmHg 7 . Severe PE was diagnosed in the presence of oliguria of less than 500 mL urine output in 24 h, cerebral or visual disturbance, pulmonary edema, epigastric or right upper quadrant pain, impaired liver function (twice the upper limit of normal levels for aspartate aminotransferase and/or alanine aminotransferase) and thrombocytopenia (platelet count <100 000/mm 3 ). The diagnosis of PE and GH was made according to the criteria of the International Society for the Study of Hypertension in Pregnancy 14 . GH was diagnosed in the presence of systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg on at least two occasions, 4 h apart and developing after 20 weeks of gestation in previously normotensive women in the absence of significant proteinuria. PE was diagnosed in the presence of GH with proteinuria of 300 mg or more in 24 h or two readings of at least ++ on dipstick analysis of midstream or catheter urine specimens if no 24 h collection was available. PE superimposed on chronic hypertension was diagnosed if significant proteinuria (as defined above) developed after 20 weeks of gestation in women with known chronic hypertension (history of hypertension before conception or presence of hypertension at the booking visit before 20 weeks of gestation in the absence of trophoblastic disease). The diagnosis of chronic hypertension was made when there was a documented presence of chronic non-GH prior to the current pregnancy or history of antihypertensive medication prior to 20 + 0 weeks. The diagnosis of white-coat hypertension was made when there were confirmed high blood-pressure recordings in the hospital/clinic with normal readings on HBPM or ambulatory monitoring.
HBPM pathway
Women eligible for the home monitoring of pregnancy hypertension pathway were counseled and trained by a specialist midwife, and supplied with an automated Microlife ® blood pressure machine (Microlife Corporation, Taipei, Taiwan), which had been validated in pregnancy and PE 15 , and with urine dipsticks. They were taught how to measure their blood pressure accurately and record readings in their notes or on a specially designed smartphone application (App) (Hampton Medical, Trakka Medical, UK). Women were given a personalized schedule of monitoring based on their underlying diagnosis, which was reviewed by the midwife every 1-2 weeks. While the schedule varied between patients, the frequency of monitoring complied with National Institute for Health and Care Excellence (NICE) guidance on hypertension in pregnancy 7 . A typical regime for a woman with well-controlled chronic hypertension would be to measure her blood pressure two or three times a week and be reviewed every 2-3 weeks, whereas a woman initiating new treatment would be asked to measure blood pressure twice a day and be reviewed 1 week later. The same specialist midwife reviewed patients at the interim visits to reduce bias.
The innovative App for smartphone users was developed to enable women to record at home their blood pressure, urinalysis results and any symptoms. The App has a set of trigger questions to determine whether they are developing PE, such as the presence of headache, epigastric pain or visual symptoms. An alert flashes up on the screen if one of the trigger questions have indicated that the woman might be developing PE or the recorded blood pressure or urine results are above the predefined thresholds, advising the woman to contact the hospital immediately. Alternatively, if the woman enters blood pressure and urinalysis results which are below the predefined thresholds and does not answer 'yes' to the trigger questions, the App will advise the patient to continue on the routine home-monitoring care pathway.
Patients in the control group presented either directly to the DAU or to the antenatal clinic. They were managed according to the hospital protocol and had all blood-pressure checks performed in the DAU.
Data collection and planned analysis
All individual patient records as well as maternity, ultrasound and neonatal databases were reviewed to collect data on patient demographics, diagnosis at the beginning of blood-pressure monitoring and at the end of pregnancy, birth details and adverse maternal, fetal and neonatal outcomes. Adverse maternal outcomes included: acute renal failure (maternal serum creatinine level > 100 μmol/L antenatally or > 130 μmol/L postnatally) or need for dialysis; acute myocardial ischemia; need for a third intravenous agent to control blood pressure (e.g. in addition to labetalol and hydralazine); hypertensive encephalopathy (altered mental status with characteristic cerebral imaging); cortical blindness; retinal detachment; stroke (ischemic or hemorrhagic); pulmonary edema or adult respiratory distress syndrome (defined as characteristic pulmonary imaging in addition to oxygen requirement); need for mechanical ventilatory support (other than for Cesarean section); disseminated intravascular coagulation; thrombotic thrombocytopenic purpura or hemolytic uremic syndrome; acute fatty liver; liver hematoma or rupture; placental abruption and maternal death. Adverse fetal outcomes included: preterm delivery (< 37 + 0 weeks' gestation); small-for-gestational age (birth weight < 10 th centile for gestational age); fetal growth restriction (birth weight < 5 th centile for gestational age) and antepartum or intrapartum fetal death. Adverse neonatal outcomes included: neonatal death; respiratory distress syndrome; intraventricular hemorrhage; necrotizing enterocolitis; bronchopulmonary dysplasia; periventricular leukomalacia; retinopathy of prematurity; seizures and admission to the neonatal unit for more than 48 h (for full-term infants).
Data on the utilization of health resources were recorded, including: the duration of blood-pressure monitoring (in weeks); the number of blood-pressure-related visits to the DAU, the hypertension clinic, the general practitioner (GP) and out-of-hours maternity triage; and the number of blood-pressure-related hospital admissions to the antenatal/postnatal ward or to the high-dependency unit for severe PE. The number of investigations for blood-pressure-related reasons was recorded, including: hematological and biochemistry tests on maternal blood and ultrasound scans for assessment of fetal growth. Administration of corticosteroids for fetal lung maturity and magnesium sulfate for severe PE was also recorded.
The healthcare economic evaluation was performed using two methods: direct cost comparison of the dataset between the two groups and process scenario modeling. The cost inputs were derived from a series of costing templates based on NICE guidelines and NHS practice reports as well as from recent scientific research papers (Table 1) 16-21 . All costs were collected in, or inflated to, 2015 values. The process modeling was based on two common scenarios: in the first, a woman develops GH and requires ongoing monitoring on an outpatient basis; in the second, a woman requires admission for control of hypertension. The differences between the scenarios based on traditional monitoring and HBPM are shown in Table 2 . The following assumptions were made to estimate costs: the midwife would be a Band 6 grade (this relates to pay scale and represents the banding of most midwives working in this area); the doctor would be either a registrar/associate specialist or a consultant (the mean hourly rate was used) and every clinic and consultation appointment was assumed to have a duration of 1 h, apart from the hypertension clinic and extra consultation sessions which were calculated to last 30 min.
In the UK, healthcare is free at the point of access and patients do not have to pay hospital bills. For this reason, bills for individual patients are not created and therefore could not be used in this analysis. Hospitals use tariffs for their services based on a coding system in order to generate funding from the state. However, this information is not easy to extrapolate, does not cover all the items we considered and is dependent on the accuracy of the information entered. Therefore, we decided to use the above methods for assessment of cost to ensure a robust review of each patient's case. 
Statistical analysis
Categorical variables were described as n (%) and continuous variables as median (interquartile range (IQR)
RESULTS
Study population
The HBPM group included 108 women, of whom 29 recorded their results on the smartphone App (App HBPM) and 79 in their medical notes (non-App HBPM). The control group comprised 58 patients. Details of patient demographics, diagnosis at the beginning of blood-pressure monitoring and at the end of the pregnancy and the duration of monitoring are outlined in Table 3 . When compared as three separate groups, there were significant differences in the body mass index (BMI) at booking (P = 0.05), ethnicity (P < 0.05) and initial diagnosis (P < 0.05) between the control, App-HBPM and non-App-HBPM groups (Table 3) . Women in the App-HBPM group had a higher BMI and were more likely to be non-Caucasian and to have an initial diagnosis of chronic hypertension. When comparing all HBPM patients with the control group, there were no significant differences in maternal age (P = 0.185), BMI (P = 0.986), ethnicity (P > 0.05), parity (P = 0.871) or smoking status (P = 0.673). Differences in the underlying initial diagnosis remained, with significantly more women in the HBPM group having chronic hypertension compared with those in the control group (49.1% vs 25.9%, P = 0.004). The HBPM group had significantly longer duration of monitoring (9 weeks vs 5 weeks, P = 0.004) and started monitoring at an earlier gestational age (30 weeks vs 33.6 weeks, P = 0.001) compared with controls (Table 3) .
Direct cost comparison of study dataset
Women in the App-HBPM cohort visited the DAU significantly fewer times over the course of the monitoring compared with women in the non-App HBPM and control groups (median (IQR); 1 (0-3) vs 5 (2-7) and 6 (5-8), respectively, P < 0.001); however, they attended the hypertension clinic significantly more times than did the other two groups (P < 0.001) ( Table 4 ). There were no differences in the number of visits to the midwifery clinic (P = 0.14), obstetric clinic (P = 0.19), GP (P = 0.67) or triage (P = 0.12). The average costs per patient for the duration of monitoring and the average weekly cost per patient based on this direct comparison of use of antenatal services are shown in Table 5 . The mean saving per week for the total HBPM group compared with the control group was £200.69, while the average saving per week for the App-HBPM cohort compared with the control group was £286.53.
Process modeling
In Scenario 1, the cost per DAU visit was calculated as (29.33 + 34.44 + (2.65 + 2.78 + 2.12) + 27.00) = £98.32 ((midwife compensation for 40 min) + (doctor compensation for 20 min) + (blood tests cost) + (fetal CTG cost)). The weekly cost per patient undergoing traditional monitoring would be £196.64 if they visited the DAU twice, and £294.96 if they visited the DAU three times per week. For patients using HBPM, the weekly cost per patient having one DAU visit per week would be £98.32 and for those visiting the DAU once every fortnight it would be £49.16. Therefore, the cost saving by using Data are given as median (interquartile range) or n (%). Comparison of: *control vs all HBPM or †control vs App HBPM vs non-App HBPM. ‡At commencement of blood-pressure monitoring. BMI, body mass index; CH, chronic hypertension; GA, gestational age; GH, gestational hypertension; MA, maternal age; PE, pre-eclampsia; WCH, white-coat hypertension.
Table 4
Number of visits to antenatal services for blood-pressure-related reasons per patient, according to whether they had home blood-pressure monitoring (HBPM), using smartphone application (App) or not, or were managed according to local protocol (controls)
HBPM
Antenatal service
Data are given as median (interquartile range).
HBPM instead of traditional monitoring for Scenario 1 was between £98.32 and £245.80 depending on the number of visits reduced. In Scenario 2, the cost per incident for each patient managed according to local protocol would be ((midwife compensation) + (doctor compensation) + (blood tests cost) + (fetal CTG cost) + (potential ambulance services cost) + (cost for initial bed day)) + (cost for x extra bed days) = £1542 + £283x. For HBPM patients, the cost of this scenario would be similar if it did occur. However, it was anticipated and modeled that this would be an infrequent occurrence, thus leading to significant cost savings.
DISCUSSION
Summary of findings
Our findings demonstrate that, in hypertensive pregnant women, HBPM reduces the number of antenatal outpatient appointments for blood-pressure-related reasons compared with management according to existing local guidelines, and therefore reduces the weekly cost of blood-pressure monitoring per patient. We have demonstrated these findings using two methods of cost evaluation: direct cost comparison of the study dataset and process scenario modeling. There was no difference in the number of adverse maternal, fetal or neonatal outcomes between the two groups. Subanalysis of the HBPM cohort suggests that the adjunct of a smartphone App could further reduce the weekly cost of monitoring per patient.
Interpretation and comparison with the literature
HBPM appears to be a cost-saving alternative to traditional monitoring for the management of hypertensive pregnant women. This finding is likely to be of importance to clinicians, patients and policy-makers. Similar cost analysis has been performed in other areas of obstetrics. For example, in a study of home-monitoring for signs of preterm labor, Morrison et al. 22 demonstrated cost savings using telemedicine services in comparison to standard care. In a retrospective modeling study evaluating the cost-effectiveness of telemonitoring in high-risk pregnant women, Buysse et al. 23 included hypertensive women in their high-risk cohort. However, their analysis included all the diagnoses together and the savings predicted were hypothetical. Our finding of a reduction in the hospital visits using HBPM without an increase in adverse outcomes is supported by previous studies of HBPM in hypertensive and normotensive pregnant women 12, [24] [25] [26] .
Strengths and limitations
Our study has several strengths. Firstly, the fact that the control group were managed without the knowledge of being included in a cost analysis could potentially reduce the risk of bias, as it gives a true reflection of the cost of current management. Secondly, two different methods of cost evaluation were used. The consistent finding of cost reduction in the HBPM group gives further credibility to the concept that HBPM is cost saving compared with traditional monitoring. Finally, the two groups were similar in terms of maternal demographics which is important when comparing not only the cost of monitoring but also the adverse outcomes between the groups.
One of the limitations of our study is that, although there was no difference in the maternal demographics between the two groups, there were differences in the underlying hypertensive disorder, with significantly more women having chronic hypertension in the HBPM cohort. The patients in this group were also monitored for a longer period. It is possible that these patients had a more stable disease process and were therefore deemed to require less frequent monitoring, influencing the number of visits and therefore the cost of monitoring. Another limitation is that the process modeling technique of cost evaluation is based on several assumptions, such as that every attendance to the DAU lasts 60 min. We recognize that this may not be representative of real clinical situations, which vary with respect to duration due to several factors. In this study, we did not include the cost of antihypertensive medication or costs to the patient themselves in the cost evaluation. This is something to be considered in future studies. The results of our study relate only to antenatal practice in the UK and the cost savings therefore may not occur in other settings. Finally, it is possible that incorrect entries were recorded by patients and this could influence results; however, it is also possible for healthcare professionals to document a result incorrectly. Bluetooth or wireless technology could resolve this potential problem by transmitting the result directly from device to output.
Clinical and research implications
Hypertensive disorders of pregnancy remain an important healthcare problem and cause of maternal morbidity and mortality. While advances have been made in recognizing women at risk and offering preventive treatment 7, 27, 28 , little has changed in the way women are monitored and treated once they have been diagnosed with hypertension in pregnancy. HBPM offers several advantages over traditional monitoring: it is more accurate and can allow for diagnosis of white-coat hypertension and masked hypertension; it offers autonomy to patients; allows for more frequent monitoring (patients check their blood pressure daily compared with two or three times a week in traditional monitoring), which enables earlier detection of hypertension and, from the findings of this study, it appears to be cost-saving. While our study may not be powered to assess differences in adverse outcomes, other small studies of HBPM in hypertensive pregnant women also reported no increase in adverse outcomes [24] [25] [26] . Our findings support the notion that a larger prospective study of HBPM in a hypertensive pregnant population is feasible and safe. Any such study should consider economic evaluation as part of its analysis.
Innovation in healthcare, including the use of smartphone and remote monitoring technology, has been recognized for its potential to improve patient care. The European Union eHealth action plan states that the development of mobile Apps to support patients' autonomy and provide a better quality of care should be a research priority 29 . In their review article, Lanssens et al. 30 demonstrate that the uptake of eHealth and telemonitoring has been relatively low in obstetrics, with only 14 studies identified. It is estimated that around 30% of the worldwide population own and use a smartphone whilst over 60% own and use a mobile phone with these figures projected to grow further 31 . This highlights the potential for eHealth and innovative models of patient-centered care in both high-and low-income countries.
Conclusion
HBPM appears to be cost saving compared with the traditional monitoring pathway in hypertensive pregnancies, without compromising maternal, fetal or neonatal health. Larger studies are now warranted to confirm these findings. If affirmed, such pathways have the potential to improve care for women with pregnancy hypertension worldwide.
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